• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Eli Lilly touts long-term safety data for Olumiant amid classwide scrutiny on JAK meds

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Nov 10, 2021 at 10:02: PM
via Eli Lilly’s Olumiant has been dragged into a classwide safety review of JAK medicines that originated from Pfizer’s Xeljanz. Hoping to convince doctors that its offering doesn’t share the problems at the same magnitude, the Indianapolis pharma is turning to long-term data.

article source
 




Top Bottom
Back
Quote